Results 191 to 200 of about 51,256 (234)

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Pediatric Ambulatory Blood Pressure Patterns and Cardiovascular Risk. [PDF]

Curr Hypertens Rep
Sill J, Urbina E.
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

The theory of hypertensive heart disease and heart failure: revisiting the evidence and pathophysiology. [PDF]

J Hypertens
Bellicini MG.
europepmc   +1 more source

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Hypertension Treatment with Angiotensin Receptor Blockers and Other Antihypertensive Agents: A Real-World Registry from a High-Volume Specialized Center Over TwoDecades. [PDF]

High Blood Press Cardiovasc Prev
Tocci G, Nardoianni G, Pala B, Russo M, Dutti GM, Giovanna G, Battistoni A, Barbato E, Volpe M.   +8 more
europepmc   +1 more source

Direct evidence implicating the asymmetrical dimethylarginine (ADMA)‐dimethylarginine dimethylaminohydrolase 1 (DDAH1) pathway in cerebrovascular dysfunction and stroke pathogenesis in mice

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Asymmetrical dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS), whereas dimethylaminohydrolase 1 (DDAH1) is primarily responsible for its metabolism. However, the roles of DDAH1 in cerebrovascular regulation are poorly understood. Furthermore, despite evidence that elevated ADMA levels are
Arun Flynn, Alexandra Riddell, Ashton Bernard, Jennifer Haggarty, Stefan Weidt, Jawza Alenazi, Erika Trabold, Delyth Graham, Laura B. Dowsett, James Leiper, Alyson A. Miller   +10 more
wiley   +1 more source

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source

Associations of triglyceride-glucose-body mass Index and C-reactive protein with isolated nocturnal hypertension: evidence from a retrospective observational study. [PDF]

Front Cardiovasc Med
Kaynak C.
europepmc   +1 more source

Highlights of the 2026 Korean Society of Hypertension guidelines for the management of hypertension: what's new and what has changed. [PDF]

Clin Hypertens
Lee EM, Cho IJ, Kang HT, Kim KI, Kim DH, Kim JH, Kim HL, Kim HC, Kim HJ, Koh ES, Park S, Park JM, Shin JH, Lee J, Lee HY, Lee H, Jung MH, Cho EJ, Choi S, Ihm SH, Committee of Korean Society of Hypertension Guidelines for the Management of Hypertension.   +20 more
europepmc   +1 more source